Biosimilars

The Pharmacy Times® Biosimilars Resource Center is a comprehensive resource for clinical news and expert insights on issues related to biosimilar drugs, a biological product that is highly similar to a reference biologic for which there are no clinically meaningful differences in terms of safety, purity, and efficacy.

Latest News

fda on paper texture - Image credit: Araki Illustrations | stock.adobe.com
Denosumab-bnht Biosimilar Receives FDA Approval

March 27th 2025

The biosimilar is approved for all indications of the reference products, Prolia and Xgeva.

Man scratch oneself, dry flaky skin on hand with psoriasis vulgaris, eczema and other skin conditions like fungus, plaque, rash and patches. Autoimmune genetic disease - Image credit: Ольга Тернавская | stock.adobe.com
Ustekinumab Biosimilar Launches in the US

March 20th 2025

biosimilar word or concept represented by wooden letter tiles on a wooden table with glasses and a book - Image credit: lexiconimages | stock.adobe.com
As Biosimilar Substitutions Become More Common, Education and Patient Counseling Are Paramount

March 14th 2025

Nighttime Close-up of Biologic Drug Packaging, Detailed Surface Texture - Image credit: Achiraya | stock.adobe.com
Pharmacists Play a Crucial Role in Adalimumab Biosimilars for Patient Care

March 5th 2025

Image Credit: © Postmodern Studio - stock.adobe.com
FDA Approves Biosimilars Referencing Denosumab for Osteoporosis-, Cancer-Related Skeletal Events

March 4th 2025

More News